A Woodbridge, CT bioscience company said it has developed a product that can act as an on/off switch for certain immunotherapy treatments, raising hopes that it can one day be used to eliminate toxic side effects that often accompany such therapies.
Uday Khire, founder and CEO of Cheminpharma, said his company’s Aquashield 1, or AS-1, was able to control CAR T cell activity in mice.